Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-2: use in solid tumors

R M Bukowski1, D McLain, T Olencki

  • 1Experimental Therapeutics Program, Cleveland Clinic Cancer Center, OH 44195.

Stem Cells (Dayton, Ohio)
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MicroRNA expression profiling in metastatic cutaneous squamous cell carcinoma.

Journal of the European Academy of Dermatology and Venereology : JEADV·2015
Same author

Advanced mesospheric temperature mapper for high-latitude airglow studies.

Applied optics·2014
Same author

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.

British journal of cancer·2014
Same author

Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer.

Oncogene·2009
Same author

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2009
Same author

Clinical Features of ANA Positive and ANA-Negative Patients with Fibromyalgia.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same journal

Correction to: Mitochondrial Transfer from Mesenchymal Stem Cells to Macrophages Restricts Inflammation and Alleviates Kidney Injury in Diabetic Nephropathy Mice via PGC-1α Activation.

Stem cells (Dayton, Ohio)·2026
Same journal

Correction to: Critical role of the potential O-linked glycosylation sites of CXCR4 in cell migration and bone marrow homing of hematopoietic stem progenitor cells.

Stem cells (Dayton, Ohio)·2026
Same journal

Brent A. Reynolds, pioneer of adult neural stem cell biology.

Stem cells (Dayton, Ohio)·2026
Same journal

CircVapa promotes the abnormal differentiation of small intestinal epithelial stem cells in diabetic state.

Stem cells (Dayton, Ohio)·2026
Same journal

Transforming Growth Factor beta-2 (TGFβ2) Drives Trabecular Meshwork Progenitor Cell Differentiation Through SMAD2/3 Signalling.

Stem cells (Dayton, Ohio)·2026
Same journal

Circular RNA circEGFR overexpression attenuates chemosensitivity and enhances cancer stemness via targeting IGF2BP2/SOX2 in breast cancer cells.

Stem cells (Dayton, Ohio)·2026
See all related articles

Recombinant interleukin-2 (rIL-2) therapy showed promise in treating solid tumors, particularly malignant melanoma and renal cell carcinoma. Further research is ongoing to understand its antitumor mechanisms and identify response predictors.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Recombinant interleukin-2 (rIL-2) is a key cytokine for T cell regulation.
  • Clinical trials are exploring rIL-2's efficacy in various solid tumors.

Purpose of the Study:

  • To summarize Phase I/II clinical trials of rIL-2 regimens in 337 patients with solid tumors.
  • To evaluate response rates and toxicity of different rIL-2-based treatments.

Main Methods:

  • Administered rIL-2 or PEG-IL-2 as single agents or in combination with interferon alpha, IL-4, or doxorubicin.
  • Included trials with tumor-infiltrating lymphocytes (TILs).
  • Focused on patients with renal cell carcinoma, malignant melanoma, and other solid tumors.

Main Results:

Related Experiment Videos

  • Response rates were 12% for renal cell carcinoma, 20% for malignant melanoma, and 2% for miscellaneous solid tumors.
  • Toxicity was dose- and schedule-dependent.
  • rIL-2 demonstrated activity in malignant melanoma and renal cell carcinoma.

Conclusions:

  • rIL-2-based regimens show clinical activity in specific solid tumors.
  • Further studies are needed to elucidate mechanisms of action and identify biomarkers for response.